Consensus Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.6947 ^USD	-0.91%		-1.46%	-8.17%

Apr. 26	Citius Pharmaceuticals Launches $15 Million Offering	MT
Apr. 11	Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	CI

Evolution of the average Target Price on Citius Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

23b2e51841d43833586df.NEHbzxKbhyCj-4jhiSJJY8Stm0dzoruF8zyDe2PE-Cc.RHHj-WHYslntoe2YwkM_DPTu3BAf8YvptXXADSCdkUhzd6O6d_izRcHPuA~da877730731e2f636ed8064b582c697c

Analyst Recommendations on Citius Pharmaceuticals, Inc.

HC Wainwright Adjusts Citius Pharmaceuticals Price Target to $4 From $6, Maintains Buy Rating	23-08-01	MT
HC Wainwright Adjusts Citius Pharmaceuticals Price Target to $6 From $4, Maintains Buy Rating	22-01-18	MT
Maxim Group Initiates Coverage on Citius Pharmaceuticals With Buy Rating, $4 Price Target	21-11-30	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6947 USD

Average target price

4 USD

Spread / Average Target

+475.79%

High Price Target

4 USD

Spread / Highest target

+475.79%

Low Price Target

4 USD

Spread / Lowest Target

+475.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Citius Pharmaceuticals, Inc.

HC Wainwright
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar